Alzheimer. Alzheimer disease
Conditions
Interventions
Intervention 1: The First Group: Patients are treated with quetiapine , 12.5 mg in night and rise to 25 to 50 mg according to patient condition.another group received placebo. Intervention 2: The Sec
Placebo
Treatment - Drugs
The First Group: Patients are treated with quetiapine , 12.5 mg in night and rise to 25 to 50 mg according to patient condition.another group received placebo.
The Second Group: Patients are treated with risperidone alone, 0.5 mgr in night and rise to 1 to 2 mg daily according to patient condition combined with a cobalamin 500 mg daily.
The Third Group: Patients received risperidone combined with a cobalamin 500 mg daily, another group received placebo.
The fourth Group:Patients are treated with quetiapine, 12.5 mg in night and rise to 25 to 50 mg according to patient condition with a cobalamin 500 mg daily,.
Sponsors
Rafsanjan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
64 Years to 84 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria In this study is: (Alzheimer diagnosis in elderly patients is carried out on basis of clinical interviews; DSM IV diagnosis criteria; medical history; clinical examinations; MRI and brain CT scan results and the mini mental state examination score; Patients who have mini mental score above than are studied; patient with Brief Psychiatric Rating Scale score 30-70) Exclusion criteria (Patients who were taking anti-psychotic medication; has schizophrenia symptoms; preliminary psychotic disorders; delirium; psychoses followed by drug or medication take; Other medical background disorders like B12 deficiency and hypothyroidism; Patients needed to be hospitalized; Patients posed to suicide commitment risk; Other causes of dementia like brain tumors; strokes; normal pressure hydrocephalus; Underlying medical conditions; that may cause behavioral or psychotic symptoms or delirium such as infection, medications with anticholinergic effects; corticosteroid use; or neurological insults is the first step in the decision-making process for treatment. In addition, the patients were discarded from the procedure if they need further medical intervention and other drugs according to their health status or families’ remark.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: 2week,4week,8week. Method of measurement: Visual Analogue Scale For Pain Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Psychiatric symptoms. Timepoint: Before treatment , 2 weeks and 8 weeks after treatment. Method of measurement: Brief Psychiatric Rating Scale Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Kazemi Arababadi
Rafsanjan University of Medical Sciences
Outcome results
None listed